Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition.
Saved in:
| Title: | Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition. |
|---|---|
| Authors: | Gorini G; Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, Maryland, United States of America., Fourati S; Department of Pathology, Case Western Reserve University, Cleveland, Ohio, United States of America., Vaccari M; Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, Maryland, United States of America., Rahman MA; Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, Maryland, United States of America., Gordon SN; Department of Infectious Diseases, GlaxoSmithKline R&D, Research Triangle Park, North Carolina, United States of America., Brown DR; Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, Maryland, United States of America., Law L; Department of Immunology, Center for Innate Immunity and Immune Disease, and Washington National Primate Research Center, University of Washington, Seattle, Washington, United States of America., Chang J; Department of Immunology, Center for Innate Immunity and Immune Disease, and Washington National Primate Research Center, University of Washington, Seattle, Washington, United States of America., Green R; Department of Immunology, Center for Innate Immunity and Immune Disease, and Washington National Primate Research Center, University of Washington, Seattle, Washington, United States of America., Barrenäs F; Department of Immunology, Center for Innate Immunity and Immune Disease, and Washington National Primate Research Center, University of Washington, Seattle, Washington, United States of America., Liyanage NPM; Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, Maryland, United States of America., Doster MN; Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, Maryland, United States of America., Schifanella L; Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, Maryland, United States of America., Bissa M; Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, Maryland, United States of America., Silva de Castro I; Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, Maryland, United States of America., Washington-Parks R; Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, Maryland, United States of America., Galli V; Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, Maryland, United States of America., Fuller DH; Department of Immunology, Center for Innate Immunity and Immune Disease, and Washington National Primate Research Center, University of Washington, Seattle, Washington, United States of America., Santra S; Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America., Agy M; Division of Surgical Sciences, Duke University School of Medicine, Durham, North Carolina, United States of America., Pal R; Advanced Bioscience Laboratories, Rockville, Maryland, United States of America., Palermo RE; Department of Immunology, Center for Innate Immunity and Immune Disease, and Washington National Primate Research Center, University of Washington, Seattle, Washington, United States of America., Tomaras GD; Division of Surgical Sciences, Duke University School of Medicine, Durham, North Carolina, United States of America., Shen X; Division of Surgical Sciences, Duke University School of Medicine, Durham, North Carolina, United States of America., LaBranche CC; Division of Surgical Sciences, Duke University School of Medicine, Durham, North Carolina, United States of America., Montefiori DC; Division of Surgical Sciences, Duke University School of Medicine, Durham, North Carolina, United States of America., Venzon DJ; Biostatistics and Data Management Section, National Cancer Institute, Bethesda, Maryland, United States of America., Trinh HV; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America., Rao M; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America., Gale M Jr; Department of Immunology, Center for Innate Immunity and Immune Disease, and Washington National Primate Research Center, University of Washington, Seattle, Washington, United States of America., Sekaly RP; Department of Pathology, Case Western Reserve University, Cleveland, Ohio, United States of America., Franchini G; Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, Maryland, United States of America. |
| Source: | PLoS pathogens [PLoS Pathog] 2020 Mar 12; Vol. 16 (3), pp. e1008377. Date of Electronic Publication: 2020 Mar 12 (Print Publication: 2020). |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101238921 Publication Model: eCollection Cited Medium: Internet ISSN: 1553-7374 (Electronic) Linking ISSN: 15537366 NLM ISO Abbreviation: PLoS Pathog Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1553-7374 |
|---|---|
| DOI: | 10.1371/journal.ppat.1008377 |
